BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32360001)

  • 21. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
    Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification.
    Ishida H; Lam AK
    Crit Rev Oncol Hematol; 2020 Jan; 145():102835. PubMed ID: 31864179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High minichromosome maintenance protein 7 proliferation indices: a powerful predictor of progression in pancreatic neuroendocrine neoplasms without distant metastasis at the time of surgery.
    Ban X; Yan J; Yu S; Lu Z; Chang X; Jia C; Gao C; Shao H; Wu Y; Mao X; Zhang Y; Li Y; Chen J
    Hum Pathol; 2019 Mar; 85():101-111. PubMed ID: 30447299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database.
    Yang Z; Shi G
    Eur J Surg Oncol; 2022 Oct; 48(10):2181-2187. PubMed ID: 35623986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia.
    Inzani F; Petrone G; Rindi G
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):463-470. PubMed ID: 30098710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
    Karakuş E; Helvacı A; Ekinci O; Dursun A
    Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.
    Lam AK; Ishida H
    Histol Histopathol; 2021 Apr; 36(4):367-382. PubMed ID: 33305819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors.
    Oba A; Kudo A; Akahoshi K; Kishino M; Akashi T; Katsuta E; Iwao Y; Ono H; Mitsunori Y; Ban D; Tanaka S; Eishi Y; Tateishi U; Tanabe M
    J Gastroenterol; 2017 Oct; 52(10):1140-1146. PubMed ID: 28488114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
    Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome.
    Dioguardi Burgio M; Cros J; Panvini N; Depoilly T; Couvelard A; Ruszniewski P; de Mestier L; Hentic O; Sauvanet A; Dokmak S; Faccinetto A; Ronot M; Vilgrain V
    Eur Radiol; 2021 Nov; 31(11):8671-8681. PubMed ID: 33977308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.
    Andreasi V; Ricci C; Partelli S; Guarneri G; Ingaldi C; Muffatti F; Crippa S; Casadei R; Falconi M
    J Endocrinol Invest; 2022 Apr; 45(4):705-718. PubMed ID: 34773595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The characteristics of serum lipid spectrum in PanNENs and its correlation with clinicopathological features and prognosis.
    Meng YF; Fan ZY; Yang J; Li YZ; Liu SJ; Gao CH; Gao X; Pang CY; Zhan HX
    Front Endocrinol (Lausanne); 2023; 14():1137911. PubMed ID: 37033225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
    Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
    World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
    Yao W; Wang W; Li G
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors.
    Gao SW; Huang CS; Huang XT; Chen LH; Chen W; Cai JP; Yin XY
    Pancreas; 2019 Jul; 48(6):795-798. PubMed ID: 31210659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients.
    Shiba S; Morizane C; Hiraoka N; Sasaki M; Koga F; Sakamoto Y; Kondo S; Ueno H; Ikeda M; Yamada T; Shimada K; Kosuge T; Okusaka T
    Pancreatology; 2016; 16(1):99-105. PubMed ID: 26718527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.
    Desai GS; Pande P; Chhabra V; Shah RC; Jagannath P
    Indian J Gastroenterol; 2019 Oct; 38(5):399-410. PubMed ID: 31802438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.
    Shen C; Chen H; Chen H; Yin Y; Han L; Chen J; Tang S; Yin X; Zhou Z; Zhang B; Chen Z
    BMC Gastroenterol; 2016 Sep; 16(1):111. PubMed ID: 27613657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.